Login to Your Account

Takeda validates Crescendo's platform to the tune of $790M

By Nuala Moran
Staff Writer

Monday, October 10, 2016

LONDON – Crescendo Biologics Ltd has landed the first major partner for its Humabody pared back antibody constructs, agreeing an oncology collaboration worth up to $790 million with Takeda Pharmaceuticals Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription